Abstract
Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm-defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK, and KRAS. The success of targeted therapy is limited by drug-tolerant tumor cells which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.
Introduction
Targeted therapies have revolutionized the treatment of Non-Small Cell Lung Cancer (NSCLC) by specifically attacking genetic drivers such as EGFR, ALK, and KRAS. Despite high initial response rates, these treatments rarely achieve a complete cure. Most patients eventually experience a state of "residual disease," where a small subpopulation of cancer cells—known as drug-tolerant persisters (DTPs)—survives the initial treatment.
These persisters do not necessarily harbor new genetic mutations; instead, they undergo a non-genetic adaptation, entering a dormant or slow-growing state that allows them to withstand the drug's effects. Over time, this residual reservoir serves as the foundation for the evolution of fully drug-resistant tumors. Understanding the molecular mechanisms that sustain these cells is critical for developing therapies that can eliminate residual disease before permanent resistance takes hold.
The FAK-YAP Signaling Axis
This research identifies a critical signaling bridge between Focal Adhesion Kinase (FAK) and the transcriptional co-activator YAP that drives the survival of DTPs. While YAP was previously known to contribute to cancer progression, this study reveals that FAK acts as the essential upstream driver that promotes YAP’s nuclear localization during targeted drug treatment.
Crucially, this activation occurs via a non-canonical pathway. Unlike the standard Hippo pathway regulation, FAK promotes YAP stability and nuclear activity through direct phosphorylation at the Tyr357 residue. This FAK-YAP axis appears to be a conserved survival mechanism across multiple lung cancer subtypes, including EGFR-mutant, ALK-fusion, and KRAS-mutant models, suggesting it is a fundamental response to oncogenic signaling inhibition.
Methodology and Data Integration
To investigate this axis, the study employed a multi-disciplinary approach combining laboratory models with clinical data:
- Patient-Derived Models: The researchers utilized 3D patient-derived organoids (PDOs) and patient-derived xenografts (PDXs) to ensure that the findings reflected the complexities of human cancer.
- Single-Cell Trajectory Analysis: By using single-cell RNA sequencing (scRNAseq) and genetic barcoding, the team tracked the transition of individual cancer cells from a drug-sensitive state to a drug-tolerant state, mapping the molecular changes in real-time.
- Computational Drug Screening: The team leveraged the NIH’s LINCS L1000 database—a library of gene expression profiles from cells treated with over 20,000 compounds—to identify agents capable of reversing the gene expression signatures associated with residual disease.
- Clinical Validation: The study analyzed scRNAseq profiles from NSCLC patients at three distinct clinical stages: treatment-naïve, residual disease, and progressive disease (acquired resistance). This confirmed that YAP nuclear localization and FAK signaling signatures are significantly elevated during the residual disease phase compared to pre-treatment levels.
Impact on the Tumor Microenvironment
The study also found that high YAP activity does more than just protect the individual cancer cell; it actively reshapes the surrounding tumor microenvironment. High YAP levels were associated with the recruitment of immunosuppressive "M2-type" macrophages and a reduction in cytotoxic T-cells. This suggests that the FAK-YAP axis effectively shields residual disease from the patient's immune system, creating a protected niche for cancer cells to survive.
Therapeutic Implications and Results
The identification of the FAK-YAP axis provides a clear therapeutic target. The researchers tested the combination of primary targeted therapies (such as the EGFR inhibitor Osimertinib) with either FAK inhibitors (e.g., VS-4718) or TEAD inhibitors (e.g., VT104), which prevent YAP from initiating gene transcription.
Key findings included:
- Synergistic Elimination: Combining FAK or TEAD inhibition with standard targeted therapy significantly reduced the number of surviving persister cells compared to monotherapy.
- Deeper Regression: In PDX models, the combination therapy led to more profound tumor shrinkage.
- Delayed Regrowth: The dual-treatment approach significantly delayed the time it took for tumors to regrow after treatment was discontinued, indicating a substantial reduction in the residual cell reservoir.
Conclusion
This study establishes the FAK-YAP signaling axis as a hallmark of drug tolerance in lung cancer. By uncovering the non-canonical phosphorylation of YAP by FAK, the research provides a mechanistic rationale for combining FAK or TEAD inhibitors with current standard-of-care targeted therapies. As several FAK and TEAD inhibitors are currently in Phase I clinical trials, these findings offer a promising roadmap for improving the durability of treatment responses and potentially preventing the onset of acquired resistance in NSCLC patients.
Summary updated